Form 4 for NAMS NewAmsterdam Pharma Co N.V.
Accepted 2025-04-21 00:00:00 ET · period of report 2025-04-14 · accession 0000950170-25-056395 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DI | 2025-04-21 | 2025-04-14 | NAMS | LANGE LOUIS G | Dir | M - OptEx | $0.00 | +69 | 28.0K | +0.2% | $0 |
| D | 2025-04-21 | 2025-04-14 | NAMS | LANGE LOUIS G | Dir | M - OptEx | — | -69 | 137 | -33% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2025-04-14 | M | A | 69 | $0.00 | 28,049 | I See Footnote | — | — | (F1) The shares are held directly by LGLange III Trust DTD10 (the "Trust") for the benefit of the Reporting Person. The Reporting Person inadvertently reported the ownership of 3,102 ordinary shares issued upon vesting of restricted stock units ("RSUs") on March 28, 2025 to his direct holdings. Such ordinary shares are held by the Trust, and this Form 4 reflects the Reporting Person's correct direct and indirect holdings. |
| 2 | Derivative | Restricted Stock Unit | 2025-04-14 | M | D | 69 | — | 137 | D | — · — to — | 69 Ordinary Shares | (F4) The RSUs were granted on March 26, 2025 as earnout RSUs pursuant to the business combination agreement, dated as of July 25, 2022, by and among the issuer, Frazier Lifesicences Acquisition Corporation, NewAmsterdam Pharma Holding B.V., and NewAmsterdam Pharma Investment Corporation (the "BCA"). The BCA provided that certain optionholders would receive RSUs of the issuer, determined in accordance with a formula set forth in the BCA and for no additional consideration, if a certain clinical development milestone was achieved within five years of the Closing Date. The Reporting Person's right to receive the earnout RSUs became fixed and irrevocable on the Closing Date. (F2) Each RSU represents a contingent right to receive one ordinary share. (F3) 3,102 RSUs vested upon grant and 69 RSUs vested on April 1, 2025. The remaining RSUs will vest as follows, subject to the Reporting Person's continued service with the issuer as of each of the applicable vesting dates: 69 of the remaining RSUs will vest on May 1, 2025 and 68 of the remaining RSUs will vest on June 1, 2025. |